AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib
This study is ongoing, but not recruiting participants.
First Posted: March 2, 2009
Last Update Posted: October 6, 2017
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||March 29, 2018|
|Primary Completion Date:||August 8, 2011 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Submission:||November 2, 2015|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Atkins MB, Gravis G, Drosik K, Demkow T, Tomczak P, Wong SS, Michaelson MD, Choueiri TK, Wu B, Navale L, Warner D, Ravaud A. Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study. J Clin Oncol. 2015 Oct 20;33(30):3431-8. doi: 10.1200/JCO.2014.60.6012. Epub 2015 Aug 24.